Yes, people with Medicare Part D who use Restasis may be eligible for a patient assistance program called myAbbVie Assist. This article discusses whether Medicare covers Restasis, Medicare ...
Patients treated with a single interventional eyelid procedure enabled by TearCare® technology after receiving Restasis® for the first six months of the trial realized clinically meaningful ...
The Food and Drug Administration has approved Mylan’s generic Restasis (cyclosporine ophthalmic emulsion) 0.05% single-use vials (eye drops) to increase tear production in patients whose tear ...
It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a new challenge named Xiidra lies ahead.
DUBLIN, March 10, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for its Prior Approval ...
Sight Sciences Inc (NASDAQ:SGHT) released the six-month SAHARA randomized controlled trial comparing interventional eyelid procedures enabled by TearCare Technology to Restasis for dry eye disease.
MARKHAM, ON, June 7, 2018 /CNW/ - Allergan plc announced today that it has received approval from Health Canada for RESTASIS MULTIDOSE™ (Cyclosporine Ophthalmic Emulsion) 0.05%. RESTASIS MULTIDOSE™ is ...
Please provide your email address to receive an email when new articles are posted on . Allergan announced it has received FDA approval for Restasis Multidose, a preservative-free, multidose bottle ...
The US Food and Drug Administration (FDA) on Wednesday denied Allergan's third citizen petition attempting to block the agency from approving generic versions of the company's blockbuster Restasis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results